The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00498667

Enrollment

Registered

2007-07-10

Start date

2006-12-31

Completion date

2014-12-31

Last updated

2015-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Keywords

PET/CT, Aggressive non-Hodgkin Lymphoma

Brief summary

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Detailed description

Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* aggressive non-Hodgkin lymphoma b cells * age 18-70 * bilirubin less then 2 * creatinine less then 2 * Pet/CT performed post 2 cycles

Exclusion criteria

* no PET/CT post 2 cycles performed * bilirubin \>2 * creatinine more then 2 * HIV positivity

Design outcomes

Primary

Measure	Time frame
progression free survival	5 years

Countries

Israel

Outcome results